Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).
Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings on the prognostic associations of TILs in metastatic HER2-positive breast cancer (Abstract S1-04).
Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-negative disease setting.
Dawn Hershman, MD, of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, reviews findings on survivorship care plans, interventions to reduce chemotherapy-induced peripheral neuropathy, and the cardiac effects of aromatase inhibitors (Poster Discussion 4).
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).
Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor–based treatment (Abstract S4-07).
